TVRD — Tvardi Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Cara Therapeutics Announces Exploration Of Strategic Alternatives
Brief: Cara Therapeutics Says Board Approved A Streamlined Operating Plan Exploring Strategic Alternatives Focused On Maximizing Shareholder Value
U.S. STOCKS ON THE MOVE-ACI Worldwide, enCore Energy, Adobe
U.S. STOCKS ON THE MOVE-Williams-Sonoma, ACI Worldwide, enCore Energy
U.S. STOCKS ON THE MOVE-Vivani, Vanda, Sarepta
U.S. STOCKS ON THE MOVE-Broadcom, Tesla, 3M
Cara drops on scrapping of neurological condition study, strategic options plan
U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics
Cara Therapeutics discontinues neurological condition study as drug fails (updated)
Brief: Cara Therapeutics Announces Outcome Of Part A Of Kourage-1 Study Evaluating Oral Difelikefalin In Notalgia Paresthetica
Cara Therapeutics discontinues study on a neurological condition as drug fails
Cara Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cara Therapeutics Q1 Revenue USD 1.8 Million
Cara Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Cara Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cara Therapeutics Announces Fourth Quarter Results
Brief: Cara Therapeutics Q4 Revenue USD 5 Million
Cara Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Cara Therapeutics Received Notice From Nasdaq That Co Is Not In Compliance With Nasdaq's Listing Rule 5450(A)(1)